{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:12:28Z","timestamp":1789135948930,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"DOI":"10.13039\/501100018675","name":"Kids' Cancer Project","doi-asserted-by":"crossref","award":["Col Reynolds Fellowship"],"award-info":[{"award-number":["Col Reynolds Fellowship"]}],"id":[{"id":"10.13039\/501100018675","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Queensland Health","award":["Clinical Fellowship"],"award-info":[{"award-number":["Clinical Fellowship"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Noncompartmental analysis (NCA) and model-based Bayesian methods (MBMs) are used for cumulative area-under-the-concentration\u2013time curve (AUC\n                      <jats:sub>cum<\/jats:sub>\n                      ) estimates during therapeutic drug monitoring. Understanding their predictive differences can assist with switching between them and result interpretation. This study aims to compare NCA-based and MBM-based busulfan-AUC\n                      <jats:sub>cum<\/jats:sub>\n                      predictions in pediatric hematopoietic stem cell transplant recipients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Data on busulfan (administered once daily through intermittent infusion) were obtained from 4 hospitals. Busulfan concentrations were measured 3, 3.25, 4, 5, 6, 8, and 24 hours after infusion initiation over 4 treatment days. The busulfan dose, pharmacokinetic profile, and patient covariate factors were supplied to Kinetica and InsightRX Nova using the Shukla model to generate NCA-based and MBM-based busulfan exposure predictions. Differences in AUC\n                      <jats:sub>cum<\/jats:sub>\n                      estimates at the end of the treatment course were compared using a Wilcoxon signed-rank sum test and Bland\u2013Altman plots. The effect of restricting data to specific treatment days on the MBM-based predictions was also examined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Data from 89 pediatric hematopoietic stem cell transplant recipients (2304 busulfan samples) were analyzed. The MBM consistently estimated higher AUC\n                      <jats:sub>cum<\/jats:sub>\n                      values than NCA, with absolute and relative percentage differences (mean \u00b1 SD) of 2.8 \u00b1 3.1 mg\u00b7L\n                      <jats:sup>\u22121<\/jats:sup>\n                      \u00b7h and 3.4 \u00b1 3.7%, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001); 1.1% of individual comparator estimates displayed a relative percentage difference \u226515%. When using the MBM and comparing sampling across all 4 days to day 1 sampling or to day 1 and 3 sampling, 14.6% and 3.4%, respectively, of estimates displayed a relative percentage difference \u226515%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      When switching from NCA to MBM during therapeutic drug monitoring, a small increase in target busulfan AUC\n                      <jats:sub>cum<\/jats:sub>\n                      may be required to maintain similar drug exposure. Sampling on only day 1 may not accurately estimate AUC\n                      <jats:sub>cum<\/jats:sub>\n                      in all patients when using MBM.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001488","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:00:07Z","timestamp":1781575207000},"page":"686-693","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A Short Communication: Comparison of Methods to Estimate Busulfan Exposure in Pediatric Hematopoietic Stem Cell Transplant Recipients"],"prefix":"10.1097","volume":"48","author":[{"given":"Nishat","family":"Siddique","sequence":"first","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, University of Queensland, Brisbane, Queensland, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Staatz","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, University of Queensland, Brisbane, Queensland, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0104-5396","authenticated-orcid":false,"given":"Rachael","family":"Lawson","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Queensland Children's Hospital, Brisbane, Queensland, Australia; and"},{"name":"School of Medicine, University of Queensland, Child Health Research Centre, Queensland, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FTD.0b013e31829dc940","article-title":"Thirteen years' experience of pharmacokinetic monitoring and dosing of busulfan","volume":"36","author":"Buffery","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-020-00947-2","article-title":"Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in paediatric patients","volume":"60","author":"Lawson","year":"2021","journal-title":"Clin Pharmacokinet."},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bbmt.2008.12.489","article-title":"Busulfan in hematopoietic stem cell transplantation","volume":"15","author":"Ciurea","year":"2009","journal-title":"Biol Blood Marrow Transpl."},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40262-020-00877-z","article-title":"Intra-individual pharmacokinetic variability of intravenous busulfan in hematopoietic stem cell-transplanted children","volume":"59","author":"Marsit","year":"2020","journal-title":"Clin Pharmacokinet."},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/psp4.12809","article-title":"Population pharmacokinetic model for once\u2010daily intravenous busulfan in pediatric subjects describing time\u2010associated clearance","volume":"11","author":"Lawson","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10928-024-09915-w","article-title":"Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing","volume":"51","author":"Hughes","year":"2024","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"A new harmonized approach to estimate busulfan exposure predicts survival and toxicity after hematopoietic cell transplantation in children and young adults: a multicenter retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol."},{"key":"R8-20260911","first-page":"196","article-title":"Association between the magnitude of intravenous busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation","volume":"28","author":"Bogn\u00e0r","year":"2022","journal-title":"Transpl Cell Ther."},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol."},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3390\/pharmaceutics14061145","article-title":"Population pharmacokinetics of busulfan and its metabolite sulfolane in patients with myelofibrosis undergoing hematopoietic stem cell transplantation","volume":"14","author":"Dadkhah","year":"2022","journal-title":"Pharmaceutics"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/0091270012447196","article-title":"Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients","volume":"53","author":"McCune","year":"2013","journal-title":"J Clin Pharmacol."},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00280-021-04288-0","article-title":"Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation","volume":"88","author":"Lawson","year":"2021","journal-title":"Cancer Chemother Pharmacol."},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41409-023-01971-z","article-title":"Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen","volume":"58","author":"Bognar","year":"2023","journal-title":"Bone Marrow Transpl."},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"834773","DOI":"10.3389\/fped.2022.834773","article-title":"Can first-dose therapeutic drug monitoring predict the steady state area under the blood concentration-time curve of busulfan in pediatric patients undergoing hematopoietic stem cell transplantation?","volume":"10","author":"Alsultan","year":"2022","journal-title":"Front Pediatr."},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1177\/0091270009357430","article-title":"Development of a population pharmacokinetics\u2010based sampling schedule to target daily intravenous busulfan for outpatient clinic administration","volume":"50","author":"Salinger","year":"2010","journal-title":"J Clin Pharmacol."},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fphar.2020.00888","article-title":"Assessment of a model-informed precision dosing platform use in routine clinical care for personalized busulfan therapy in the pediatric hematopoietic cell transplantation (HCT) population","volume":"11","author":"Shukla","year":"2020","journal-title":"Front Pharmacol."},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/psp4.12684","article-title":"A hybrid machine learning\/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors","volume":"10","author":"Hughes","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"R18-20260911","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/FTD.0000000000001304","article-title":"Examining different methods to assess busulfan exposure in pediatric hematopoietic stem cell transplant recipients","volume":"47","author":"Thompson","year":"2025","journal-title":"Ther Drug Monit."},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/FTD.0000000000000276","article-title":"Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the BestDose software","volume":"38","author":"Neely","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/FTD.0000000000001217","article-title":"Simulation-based optimization of sampling schedules for model-informed precision dosing of once-daily and 4-times-daily busulfan in pediatric patients","volume":"46","author":"Ben Hassine","year":"2024","journal-title":"Ther Drug Monit."},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1097\/TP.0000000000000708","article-title":"Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients\u2014a prospective, randomized study","volume":"99","author":"St\u00f8rset","year":"2015","journal-title":"Transplantation"},{"key":"R22-20260911","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/FTD.0000000000001107","article-title":"Busulfan interlaboratory proficiency testing program revealed worldwide errors in drug quantitation and dose recommendations","volume":"45","author":"Kweekel","year":"2023","journal-title":"Ther Drug Monit."},{"issue":"suppl 1","key":"R23-20260911","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1182\/blood-2022-166959","article-title":"A model-informed precision busulfan dosing in pediatric patients undergoing hematopoietic cell transplantation- real-world data","volume":"140","author":"Balasubramanian","year":"2022","journal-title":"Blood"},{"key":"R24-20260911","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10928-017-9511-7","article-title":"Comparison of non-compartmental and mixed effect modelling methods for establishing bioequivalence for the case of two compartment kinetics and censored concentrations","volume":"44","author":"Hughes","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001488","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:00:30Z","timestamp":1789135230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001488","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"2025-10-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}